Clinical Value of New Staging Systems for Multiple Myeloma
1
조회
0
다운로드
1
인용
0
참고문헌
초록
Abstract
Purpose: We wanted to investigate the validity of the recently introduced Southwest Oncology Group (SWOG) staging system and the International Staging System (ISS) by comparing both systems with the widely accepted Durie/Salmon (DS) system for multiple myeloma patients. Materials and Methods: Between 1992 and 2005, 85 multiple myeloma patients (men: women 41:44, median age: 63 years (range: 36∼87)) with available baseline values of albumin and β2-microglobulin were enrolled. The clinical and laboratory data were retrospectively obtained. Results: According to the ISS, 11 patients were stage I (12.9%), 30 patients stage II (35.3%) and 44 patients stage III (51.8%). The median survivals of the ISS stages I, II and III were 78.6 months, 31.8 months and 15.1 months, respectively (p=0.015). The DS staging system was not able to predict the survival. For the SWOG staging system, 14 patients were stage I (16.4%), 27 patients stage II (31.8%), 27 patients stage III (31.8%) and 17 patients were stage IV (20.0%). The median survivals of the SWOG staging system stage I, II, III and IV were 78.6 months, 31.8 months, 11.6 months and 24.8 months, respectively (p=0.0075). Conclusion: The ISS staging system showed better reliability, simplicity and predictability for survival than the DS and SWOG staging systems for multiple myeloma patients. (Cancer Res Treat. 2007;39:171-174)
참고문헌 (10)
- Durie BG, "Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features response to treatment", pp.842~54
- Jacobson JL, "Southwest Oncology Group. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience", 122, pp.441~450 (2003)
- Greipp PR, "International staging system for multiple myeloma", 23, pp.3412~3420 (2005)
- Durie BG, "Grenier J. Serum beta2 microglobulin and survival duration in multiple myeloma a simple reliable marker for staging. Br J Haematol. 1983;55", pp.439~47
- Durie BG, "et al. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma", stock-(vack d), pp.823~30
- Durie BG, "Sany J. Prognostic factors and staging in multiple myeloma", pp.80~7
- Lust JA, "Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81", pp.3382~7
- Tricot G, "Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities", 86, pp.4250~4256 (1995)
- Kim H, "New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy", 12, pp.837~844 (2006)
- Mihou D, "Evaluation of five staging systems in 470 patients with multiple myeloma", 91, pp.1149~1150 (2006)